Brought to you by 
Pfizer acquires Esperion Therapeutics for $1.25bn
04 Mar 2004
Executive Summary
In a deal worth $1.25bn, Pfizer has acquired publicly traded Esperion Therapeutics (develops drugs for cardiovascular diseases) through a cash tender offer of about 35.6mm shares priced at $35 each, a 55% premium to the market average.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer acquires Esperion Therapeutics for $1.25bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice